Published: 2019-04-23

Study of effect of propranolol, atenolol and celiprolol on exercise induced changes in heart rate, blood pressure and peak expiratory flow rate in healthy human volunteers

Sumit P. Patel, Rima B. Shah


Background: Beta blockers are known to cause attenuation of sympathetic stimulation mediated increase in cardiovascular parameters. Very few studies are available in Indian set-up comparing these changes between different beta blockers available in market. The objective of the study was to compare efficacy and safety of propranolol, atenolol and celiprolol on heart rare, blood pressure and airway resistance, both at rest and during exercise.

Methods: A prospective interventional study was carried out involving 72 healthy volunteers in the clinical pharmacology laboratory. Participants were divided in three groups of 24 each and given single oral doses of propranolol 40 mg, Atenolol 50 mg and celiprolol 40 mg was given to the participants. Exercise given in the form of step ladder test and hand grip dynamometer and effect on the different parameters like HR, SBP, DBP and PEFR were recorded before and immediately after exercise and compared.

Results: All the three drugs were effective in attenuating the exercise induced cardiovascular parameters (p <0.05). Drug A cause change in HR, SBP, DBP and PEFR significantly (p <0.05). Change in SBP was more significant with drug B while significant difference was found in HR, SBP and DBP before and after exercise in drug C in both SL and HGD tests. No significant difference was found between the drug groups (p >0.05). No adverse effects were reported in the study participants.

Conclusions: All the three drugs are effective in attenuating cardiovascular changes after sympathetic stimulation like exercise and there was no significant difference among them.


Atenolol, Celiprolol, Hand grip dynamometer, Propranolol, Step ladder test

Full Text:



Golan DE, Tashjian AH, Armstrong EJ, Armstrong AW. Principles of pharmacology: The pathophysiologic basis of drug therapy. 2nd ed. Lippincott Williams & Wilkins; 2007.

Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang and Dale's Pharmacology. 7th ed. Elsevier: Churchill Livingstone; 2011.

Tripathi KD. Essentials of medical pharmacology. 6th ed. New Delhi: Jaypee Brothers; 2009:119.

Lopez SJ, Swedberg K, McMurray J. Expert consensus document on β-adrenergic receptor blockers. Eur Heart J. 2004;25:1341-62.

Chobanian AV, Bakris GL, Black HR. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. J of Hypertension. 2003;42(6):1206-52.

Brunton LL, Chabner BA, Knollmann BC. Goodman and Gilman's The pharmacological basis of therapeutics. 12th ed. New York (NY): The McGraw-Hill Companies; 2010:176.

Benson MK, Berrill WT, Sterling GM, Decalmer PB, Chatterjee SS, Croxson RS, et al. Cardioselective and non-cardioselective beta-blockers in reversible obstructive airways disease. Postgrad Med J. 1977;53:143.

MERIT-HF Study Group. Effect of metoprolol CR⁄ XL in chronic heart failure: metoprolol CR⁄ XL randomised intervention Trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001-7

Medhi B, Prakash A. Practical manual of experimental and clinical pharmacology. 1st ed. New Delhi (IN): Jaypee brothers; 2010:256-61.

Chamberlain DA, Turner P, Sneddon JM. Effects of atropine on heart-rate in healthy man. Lancet. 1967;290(7505):12-5.

Carruthers SG, Shanks RG, McDevitt DG. Intrinsic heart rate on exercise and the measurement of β‐adrenoceptor blockade. Br J Clin Pharmacol. 1976 Dec;3(6):991-9.

Gupta S, Wright HM. Nebivolol: A highly selective β1‐adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Therapeut. 2008;26(3):189-202.

Busst CM, Bush A. Comparison of the cardiovascular and pulmonary effects of oral celiprolol, propranolol and placebo in normal volunteers. Br J Clin Pharmacol. 1989 Apr;27(4):405-10.

Pittner H. Pharmacodynamic actions of celiprolol, a cardioselective beta-receptor blocker. Drug Res. 1983;33(1 A):13-25.

Louis WJ, Drummer OH, Fung LH. Pharmacology of celiprolol. Cardiovasc Drugs Therapy. 1990;4:1281-6.

Milne RJ, Buckley MM. Celiprolol. An updated review of its pharmacodynamics and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease. Drugs. 1991;41(6):941-69.